Abstract:Complex chromosome rearrangements (CCRs) are currently defined as structural genome variations that involve more than 2 chromosome breaks and result in exchanges of chromosomal segments. They are thought to be extremely rare, but their detection rate is rising because of improvements in molecular cytogenetic technology. Their population frequency is also underestimated, since many CCRs may not elicit a phenotypic effect. CCRs may be the result of fork stalling and template switching, microhomology-mediated bre… Show more
“…In contrast to the present de novo CCR localized in a small region of chromosome 2, most constitutional CCRs involve 2 or more chromosomes [Kloosterman and Cuppen, 2013]. To date, only a few cases of CCRs involving only a single (2) none ( chromosome have been described [López-Expósito et al, 2008;Kloosterman et al, 2012;Poot and Haaf, 2015]. The CCR in our patient is responsible of the 2q37.3 deletion (2.580 Mb) and the heterogeneity of partial trisomies involving the 2q34q37.2 region.…”
Section: Discussioncontrasting
confidence: 59%
“…In one of the cases, the CCR involved 5 chromosomes and 5-15 breakpoints [Houge et al, 2003]; in the other case, the CCR, at the PLP1 locus, included triplication and quadruplication [Beck et al, 2015]. Recently, the review of Poot and Haaf [2015] provided some guidance as to how current molecular cytogenetic techniques can be used to resolve constitutional CCRs and to determine their respective mechanisms of origin. Array-CGH is a powerful tool to identify the breakpoints involved in complex rearrangements; however, this methodology may not be appropriate for the characterization of heterogeneous rearrangements.…”
Complex chromosome rearrangements (CCRs) are unusual structural chromosome alterations found in humans, and to date only a few have been characterized molecularly. New mechanisms, such as chromothripsis, have been proposed to explain the presence of the CCRs in cancer cells and in patients with congenital disorders and/or mental retardation. The aim of the present study was the molecular characterization of a constitutional CCR in a girl with multiple congenital disorders and intellectual disability in order to determine the genotype-phenotype relation and to clarify whether the CCR could have been caused by chromosomal catastrophic events. The present CCR was characterized by G-banding, high-resolution CGH, multiplex ligation-dependent probe amplification and subtelomeric 2q-FISH analyses. Preliminary results indicate that the de novo CCR is unbalanced showing a 2q37.3 deletion and 2q34q37.2 partial trisomy. Our patient shows some of the typical traits and intellectual disability described in patients with 2q37 deletion and also in carriers of 2q34q37.2 partial trisomy; thus, the clinical disorders could be explained by additional effects of both chromosome alterations (deletions and duplications). A posterior, sequential FISH study using BAC probes revealed the unexpected presence of at least 17 different reorganizations affecting 2q34q37.2, suggesting the existence of chromosome instability in this region. The present CCR is the first case described in the literature of heterogeneity of unbalanced CCRs affecting a small region of 2q, indicating that the mechanisms involved in constitutional chromosome rearrangement may be more complex than previously thought.
“…In contrast to the present de novo CCR localized in a small region of chromosome 2, most constitutional CCRs involve 2 or more chromosomes [Kloosterman and Cuppen, 2013]. To date, only a few cases of CCRs involving only a single (2) none ( chromosome have been described [López-Expósito et al, 2008;Kloosterman et al, 2012;Poot and Haaf, 2015]. The CCR in our patient is responsible of the 2q37.3 deletion (2.580 Mb) and the heterogeneity of partial trisomies involving the 2q34q37.2 region.…”
Section: Discussioncontrasting
confidence: 59%
“…In one of the cases, the CCR involved 5 chromosomes and 5-15 breakpoints [Houge et al, 2003]; in the other case, the CCR, at the PLP1 locus, included triplication and quadruplication [Beck et al, 2015]. Recently, the review of Poot and Haaf [2015] provided some guidance as to how current molecular cytogenetic techniques can be used to resolve constitutional CCRs and to determine their respective mechanisms of origin. Array-CGH is a powerful tool to identify the breakpoints involved in complex rearrangements; however, this methodology may not be appropriate for the characterization of heterogeneous rearrangements.…”
Complex chromosome rearrangements (CCRs) are unusual structural chromosome alterations found in humans, and to date only a few have been characterized molecularly. New mechanisms, such as chromothripsis, have been proposed to explain the presence of the CCRs in cancer cells and in patients with congenital disorders and/or mental retardation. The aim of the present study was the molecular characterization of a constitutional CCR in a girl with multiple congenital disorders and intellectual disability in order to determine the genotype-phenotype relation and to clarify whether the CCR could have been caused by chromosomal catastrophic events. The present CCR was characterized by G-banding, high-resolution CGH, multiplex ligation-dependent probe amplification and subtelomeric 2q-FISH analyses. Preliminary results indicate that the de novo CCR is unbalanced showing a 2q37.3 deletion and 2q34q37.2 partial trisomy. Our patient shows some of the typical traits and intellectual disability described in patients with 2q37 deletion and also in carriers of 2q34q37.2 partial trisomy; thus, the clinical disorders could be explained by additional effects of both chromosome alterations (deletions and duplications). A posterior, sequential FISH study using BAC probes revealed the unexpected presence of at least 17 different reorganizations affecting 2q34q37.2, suggesting the existence of chromosome instability in this region. The present CCR is the first case described in the literature of heterogeneity of unbalanced CCRs affecting a small region of 2q, indicating that the mechanisms involved in constitutional chromosome rearrangement may be more complex than previously thought.
“…Несмотря на большой клинический и эксперимен-тальный материал, посвященный феномену хромо-трипсиса, механизмы его возникновения и развития остаются неясными [50,74]. Поскольку подавляющее число поломок ДНК при хромотрипсисе по своей сути является микрогомологичным [45], есть все основания считать, что репарация возникших в клетке повреж-дений ДНК осуществляется путем негомологичного концевого спаривания [75,76], что успешно исполь-зуется для его выявления.…”
Section: основные механизмы хромотрипсисаunclassified
The article presents a clinical case and literature review dwelling on the recently discovered chromothripsis phenomenon in oncology. Chromothripsis is a type of complex genome changes when a chromosome is first torn into dozens and even thousands of fragments, and then these fragments are bound in a random manner. Sometimes, several chromosomes are involved in the restructuring. As a result, genome mutant zones are formed which trigger malignancies and congenital diseases. In other words, the use of certain methodological approaches (multicolor fluorescence in situ hybridization, SKY technique, and some others) permits to observe under a microscope the splitting of two or more chromosomes and further reunification of these fragments into new unusual two- or multicolor structures, chromosomal markers. Chromothripsis is a rare phenomenon with a peculiar pattern observed in clones of cells of various tumors including hematopoietic and lymphoid tissue malignancies. There are published data on a higher incidence of this phenomenon in patients with myelodysplastic syndromes and bone tumors. TP53 gene mutations play an important role in the development of chromothripsis. The use of paired-sequencing DNA or SNP approaches in oncology is promising both in theoretical and clinical application. The first subject cohort should include patients with TP53 and MLL gene mutations, complex chromosomal aberrations, EVI-1 gene overexpression, and some others. The article presents the chromothripsis phenomenon in an 8-month-old girl with M7 acute myeloid leukemia.
“…Thereupon, the authors isolated cell clones and confirmed in clones with aneuploidy and/ or marker chromosomes by telomere fusion PCR that telomere fusion had indeed taken place. By whole-genome sequencing clusters of genomic rearrangements, affecting one or more chromosomes and exhibiting hallmarks of chromothripsis, such as close spatial clustering, random fragment orientation and oscillating copy number states were found [Korbel and Campbell, 2013;Poot and Haaf, 2015]. Those were in particular terminal deleAll linear chromosomes are capped at their ends, the telomeres, by special telomeric repeat sequences [Riethman, 2008].…”
Section: From Telomere Crisis Via Dicentric Chromosomes To Kataegis Amentioning
confidence: 99%
“…Loss of TERT activity may cause a few rare autosomal recessive, dominant and X-linked syndromes, such as dyskeratosis congenita 1, idiopathic pulmonary fibrosis and myelodysplastic syndrome, and may be involved in ageing [Armanios and Blackburn, 2013;Vermeij et al, 2015]. Single chromosomes undergo, upon loss of their telomeric repeat sequences, breakage-fusion-bridge cycles, producing dicentric chromosomes, which may subsequently be degraded into mitotically stable dicentric supernumerary marker chromosomes [Murnane, 2012;Spittel et al, 2014;Poot and Haaf, 2015]. Products of breakage-fusionbridge cycles are rarely observed, since cell cycle checkpoints prevent their proliferation.…”
Section: From Telomere Crisis Via Dicentric Chromosomes To Kataegis Amentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.